The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.
Source: iStock
Here are the 40 companies that made the FDA’s list:
- Ranbaxy Laboratories
- Sun Pharmaceutical Industries Limited
- Galena Biopharma, Inc.
- Roche Palo Alto, LLC
- Bayer AG
- Novartis AG (ADR) (NYSE:NVS)
- Mylan NV (NASDAQ:MYL)
- Acorda Therapeutics Inc (NASDAQ:ACOR)
- AstraZeneca plc (ADR) (NYSE:AZN)
- Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA)
- HLS Therapeutics, Inc
- Orphan Europe SARL
- King Pharmaceuticals Inc.
- Cubist Pharmaceuticals
- Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
- Cephalon (MM)
- ApoPharma Inc
- Shire Plc
- NPS Pharmaceuticals Inc
- Boehringer Ingelheim GmbH
- Questcor Pharmaceuticals Inc
- Pharmacia & Upjohn Inc
- Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)
- Corcept Therapeutics Incorporated (NASDAQ:CORT)
- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
- Gilead Sciences, Inc. (NASDAQ:GILD)
- Roxane Laboratories, Inc.
- Danco Laboratories LLC
- Meda Pharmaceuticals Inc
- Actelion Ltd.
- Swedish Orphan Biovitrum AB
- Celgene Corporation (NASDAQ:CELG)
- GlaxoSmithKline plc (ADR) (NYSE:GSK)
- VIVUS, Inc. (NASDAQ:VVUS)
- Hyperion Therapeutics Inc
- H. Lundbeck A/S
- Insys Therapeutics Inc (NASDAQ:INSY)
- Biogen Inc (NASDAQ:BIIB)
- Pfizer Inc. (NYSE:PFE)
- Valeant Pharmaceuticals Intl Inc (NYSE:VRX)
